PATENT CLAIM ANALYSIS

Application Number: 15882386
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["549", "462000"]

Abstract:
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Claim (Index 15):
The medicament according to  claim 14 , which is an LSD1 inhibitor.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 86.0
- Lexical Diversity: 1.74359
- Patent Class: 549.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15302405', '15467548', '15005574', '14404126', '14902388']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7812848717880758
- 35 USC 102 Novelty (BERT): 0.5320742950784315
- Combined Prediction Score: 0.7563638141171114
- Mean Citation Score: 356.25894200000016
- Max Citation Score: 360.23868
- Similarity Product: 245.30257015304088

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test